Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study).
Am J Cardiol
; 119(10): 1576-1583, 2017 05 15.
Article
en En
| MEDLINE
| ID: mdl-28343601
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Citocinas
/
Enfermedad Coronaria
/
Proproteína Convertasa 9
/
LDL-Colesterol
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Am J Cardiol
Año:
2017
Tipo del documento:
Article